← Back to Clinical Trials
Recruiting NCT05660603

NCT05660603 Circum-Psoas Blocks Versus Combined Lumbar and Sacral Plexus Blocks in Hip Fracture Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05660603
Status Recruiting
Phase
Sponsor Zagazig University
Condition Hip Fractures
Study Type INTERVENTIONAL
Enrollment 63 participants
Start Date 2022-12-20
Primary Completion 2026-02-01

Eligibility & Interventions

Sex All sexes
Min Age 60 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
controlLSPCP

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 63 participants in total. It began in 2022-12-20 with a primary completion date of 2026-02-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Hip fracture (HF) is one of the major worldwide problems that constitute a significant mortality rate, ranging from 14- 36% in the first year after injury, and is associated with profound temporary and sometimes permanent impairment of independence and quality of life in the geriatric population. Surgical treatment is considered the best option for patients with hip fractures,s especially in the elderly, however, it is associated with moderate to severe postoperative pain. Pain is one of the main factors limiting ambulation, increasing the risk of thromboembolism by immobility and causing metabolic changes that affect other systems. Therefore, individualized pain management with the use of appropriate analgesic techniques is of paramount importance. Moreover, early intervention of rehabilitation aiming at a better postoperative recovery may reduce the length of hospital stay and return to daily. Effective pain management is one of the crucial components in enhanced recovery after surgery (ERAS). • Numerous regional anesthetic techniques have been used to provide analgesia following hip fracture surgery, including intrathecal morphine, epidural analgesia, fascia iliaca block, lumber plexus block, and sacral plexus block, however, each of these techniques has specific limitations that prevent them from being the analgesic technique of choice for hip fracture surgery. To our knowledge, there is no study done to compare circum-psoas block versus the combined lumbar and sacral plexus blocks as pre-emptive analgesia in patients undergoing hip fracture surgery under general anesthesia.

Eligibility Criteria

Inclusion Criteria: * Patient acceptance. * BMI ≤ 30 kg/m2 * ASA I-III. * First unilateral surgery for hip fracture including femoral neck, intertrochanteric or subtrochanteric fracture. * Patient with planned hip fracture surgery within 24-72 hours under general anesthesia. Exclusion Criteria: * Multiple trauma, multiple fractures, or pathological fractures * Prosthetic fracture or usage of bone-cement fixation in the surgery. * Scheduled for bilateral hip fracture surgery. * Pre-existing neurological deficit in the lower extremity * Contraindication for peripheral nerve block (infection at the site of needle insertion, coagulopathy, allergy to local anesthetics used) * History of chronic pain and taking analgesics * History of cognitive dysfunction or mental illness

Contact & Investigator

Central Contact

Shereen E Abd Ellatif, MD

✉ shosh.again@gmail.com

📞 01007948840

Frequently Asked Questions

Who can join the NCT05660603 clinical trial?

This trial is open to participants of all sexes, aged 60 Years or older, studying Hip Fractures. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05660603 currently recruiting?

Yes, NCT05660603 is actively recruiting participants. Contact the research team at shosh.again@gmail.com for enrollment information.

Where is the NCT05660603 trial being conducted?

This trial is being conducted at Zagazig, Egypt.

Who is sponsoring the NCT05660603 clinical trial?

NCT05660603 is sponsored by Zagazig University. The trial plans to enroll 63 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology